Which presentation is ChondroFiller actually for?

The question most patients bring to a first consultation is simpler than it sounds: does ChondroFiller treat what I actually have?

The answer turns on one anatomical distinction. A focal cartilage defect has a defined boundary — a discrete area where the surface has worn through while the surrounding cartilage remains reasonably intact. ChondroFiller is an acellular type I collagen scaffold; placed into that kind of defect, it gives the patient's own progenitor cells a structure to migrate into and begin building new matrix. That repair process depends on a recoverable surface architecture: a contained space with defined edges.

Widespread degenerative OA is a different presentation entirely. Rather than a contained gap, the cartilage is thinned and reactive across multiple surfaces, and the joint itself is often inflamed. A scaffold designed to fill a discrete defect cannot address that pattern on its own — nor is it intended to.

The distinction matters because the pathway diverges. Widespread changes do not rule ChondroFiller out, but they call for a combined approach that also addresses joint environment — something the scaffold alone does not cover.

How the scaffold works — and why defect type matters

The scaffold works through a process called acellular matrix-induced chondrogenesis. Once placed at the defect site — via an ultrasound-guided injection, with no arthroscopy or general anaesthetic required — the type I collagen gel adheres to the exposed bone surface and creates a three-dimensional framework. Progenitor cells from the adjacent synovium and subchondral bone migrate into that framework and begin laying down new matrix; the scaffold provides the structural environment that makes this migration possible.

Think of it as temporary scaffolding rather than a permanent filler. The material does not replace cartilage immediately. Instead, it supports the body's own repair processes via acellular matrix-induced chondrogenesis, with remodelling progressing gradually over the months following treatment.

The clinical consequence follows directly from the mechanism. ChondroFiller acts at the cartilage surface — it fills a structural gap and recruits cells to rebuild within it. It does not reach the synovial lining. In widespread OA, a significant source of ongoing pain is synovial inflammation: the joint lining becomes thickened and reactive, generating discomfort independently of any discrete surface defect. A scaffold designed for surface repair cannot address that process, which is why a diffuse, inflammatory presentation calls for either a different approach or a combination that targets both structures.

When ChondroFiller is the primary pathway

Candidacy comes down to what MRI reveals about the defect's boundaries. A presentation that qualifies for ChondroFiller alone has two features: the cartilage loss is confined to a discrete area, and the surrounding surface is either intact or sufficiently recoverable to give the scaffold defined edges to fill. When imaging confirms that pattern — a contained defect rather than generalised thinning — ChondroFiller injection is the primary recommendation.

No upper age limit applies, and bone-on-bone contact does not automatically disqualify a patient. Those restrictions belong to surgical repair techniques that depend on adequate residual cartilage stock; the injection pathway carries no equivalent constraint, which meaningfully broadens who can realistically be considered.

Defect size also determines how much scaffold is required. Most focal presentations are managed with a single box; larger surface areas or multi-compartment joints may need two or three. Guide costs — confirmed by the treating clinic after imaging review — are £3,000 for one box, £5,500 for two, and £8,000 for three. The correct box count cannot be established without mapping the defect first, which is why the clinic does not quote a treatment plan before reviewing imaging.

For patients who know their defect is deep — ICRS Grade 3 or 4, or extending through subchondral bone — the injection pathway may still be appropriate. Defects of that severity have traditionally pointed towards microfracture or mosaicplasty, but those are surgical-framework comparators. Surface architecture, not depth grading alone, is the relevant determinant for scaffold placement.

MRI review is therefore the step that converts a first-pass self-assessment into an actual pathway decision.

Widespread OA: when combination therapy is the answer

Degenerative or widespread OA rarely presents as a single problem. Where focal disease is essentially structural — a defined gap in the surface — widespread OA involves two distinct processes running in parallel: loss of cartilage at the load-bearing surface and a reactive synovial lining that has become thickened and inflamed, generating pain independently of the surface damage. ChondroFiller is designed for the first of these; it cannot reach the second.

For patients whose MRI shows both processes are active — cartilage loss on the surface combined with synovial reactivity, swelling, or flares — the clinic uses the CFI+ combination pathway: ChondroFiller placed at the bone surface, with Arthrosamid delivered separately to integrate into the synovial lining. The two injections work through entirely different mechanisms. ChondroFiller is a regenerative scaffold that recruits the body's own progenitor cells to rebuild structural matrix; Arthrosamid is a non-regenerative polyacrylamide hydrogel providing mechanical cushioning within the synovial compartment, with symptom relief documented over approximately two to three years. Combining them is not additive within the same tissue — it is complementary across two anatomically distinct structures.

This distinction matters clinically. Arthrosamid does not address surface architecture; ChondroFiller does not address synovial inflammation. Neither substitutes for the other. In the CFI+ pathway, ChondroFiller remains the regenerative component and Arthrosamid the synovial-compartment complement — a co-treatment within a combination strategy rather than an alternative in its own right.

A practical consequence is that both injections can be co-delivered in a single appointment, guided by imaging that has already mapped both the surface defect and the synovial picture.

How the pathway decision is made in practice

Once imaging is in hand, the assessment turns to defect characterisation: boundaries, depth, subchondral involvement, and whether damage has spread across more than one compartment. These variables — not age or Kellgren–Lawrence grade in isolation — are what convert a presenting complaint into a pathway assignment.

KL grade provides a useful starting reference, but it does not resolve whether remaining damage is focal or diffuse, nor does it capture synovial reactivity. Two patients arriving with identical KL scores can leave with different plans: one with a discrete ICRS Grade 4 lesion and an otherwise recoverable surrounding surface may suit ChondroFiller alone; the other, with the same radiographic grade but multi-compartment thinning and a reactive synovial picture, may fit the CFI+ combination. The pathway follows anatomy, not the number on the radiology report.

The timing of that conversation carries its own logic. The clinic's approach is guided by a preservation-first principle: addressing a defect while the surrounding cartilage still provides structural context keeps the widest range of treatment options available. This is grounded in clinical reasoning about scaffold biology and defect architecture — the evidence base for long-term comparative outcomes in injection-delivered scaffold therapy is still developing — but the practical force is clear. A joint assessed at KL2 or KL3 generally offers more to work with than one reviewed only once pain has become disabling.

The consultation is, in this sense, less a triage exercise than a synthesis: imaging findings, symptom pattern, and structural characterisation read together to identify which pathway — ChondroFiller alone, CFI+ combination, or a primarily synovial approach — fits the specific joint in question.

Where this sits relative to surgery and palliative injections

Hyaluronic acid viscosupplementation and PRP address symptoms rather than structure. Both are intra-articular injections that can reduce discomfort in appropriate patients, but neither modifies the surface architecture of a focal defect — the underlying gap remains after treatment.

Surgical cartilage repair sits at the other end of the spectrum. Microfracture and mosaicplasty are established for smaller focal defects; for areas of 3 cm² or more, MACI has demonstrated superior KOOS pain and function scores at two and five years compared to microfracture. Those outcomes are clinically meaningful, but the pathway involves arthroscopy, general anaesthetic, and a rehabilitation commitment that is neither feasible nor appropriate for every patient.

ChondroFiller injection occupies the space between the two. It introduces a regenerative scaffold into a defined defect — addressing surface architecture in a way that palliative injections cannot — without requiring the theatre infrastructure surgery involves. That intermediate position is available precisely because the collagen matrix is injectable; delivery does not require an arthroscopic step.

For a patient with a confirmed focal defect who is not yet a surgical candidate, or who is pursuing a non-operative route first, this positioning is clinically relevant. The practical question is not whether such a pathway exists but whether a specific patient's imaging supports it — and that is the determination a specialist consultation is designed to make. Reviewing defect boundaries, depth, and the wider joint picture, an assessment at London Cartilage Clinic on Harley Street establishes whether injection alone, combination therapy, or surgical referral is the appropriate next step; further detail is available at londoncartilage.com.